Related Experiment Video
Updated: Feb 3, 2026
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
CXCL9 chemokine in ulcerative colitis
1Department of Clinical and Experimental Medicine, University of Pisa.
Abstract:
The aim of this narrative review is to highlight the role of CXCL9 in Ulcerative Colitis (UC), in order to understand the mechanism underlying the inflammation in UC and to investigate also if Th1-chemokines could be useful as a marker of disease. It was shown that chemokine (C-X-C motif) receptor (CXCR)3 and its ligand chemokine, monokine induced by interferon (IFN)-γ(MIG)/ chemokine (C-X-C motif) ligand 9 (CXCL)9, are highly overexpressed both in the intestinal mucosa of mice with experimental colitis and in patients with UC (specifically, in lymphocytes, macrophages and epithelial cells). In epithelial colonic cells CXCL9 expression is increased by IFN-γ. MIG has an important role in the recruitment of mononuclear cells and granulocytes, so in maintaining the inflammation in UC. Since serum CXCL9 levels are related with UC disease activity, it could be a marker for the responsiveness of patients to treatments. It has been recently suggested that blocking CXCL9 may be a potentially effective therapy for moderately-to-severely active UC.
More Related Videos
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
15:49Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
Published on: October 16, 2013
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...